Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (31-40 of 224) with videos related to

Pageof 23
Sort By:
Hematology/Oncology Clinics of North America|July 17, 2025
The Rapidly Evolving Landscape of the Biology and Therapy of Chronic Lymphocytic LeukemiaJennifer R Brown, Matthew S Davids
Seminars in Hematology|March 27, 2024
Therapeutic targeting of apoptosis in chronic lymphocytic leukemiaInhye E Ahn, Matthew S Davids
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphomaSamuel Y Ng, Matthew S Davids
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2023
Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?Othman Al-Sawaf, Matthew S Davids
Leukemia & Lymphoma|May 6, 2014
Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?Elizabeth A Brem, Matthew S Davids
Blood|March 6, 2020
Breaking through BCL-2 inhibition in CLLStephen J F Chong, Matthew S Davids
Blood|July 18, 2018
The rise of apoptosis: targeting apoptosis in hematologic malignanciesRebecca Valentin, Stephanie Grabow, Matthew S Davids
Blood Cancer Journal|January 8, 2026
First-line treatment for CLL in the era of targeted therapyMatthew S Davids, Stephan Stilgenbauer, Constantine S Tam
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2024
PI3K Inhibitors in Hematology: When One Door Closes…Sigrid S Skånland, Klaus Okkenhaug, Matthew S Davids
Leukemia & Lymphoma|April 26, 2013
Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibitionMatthew S Davids, Anthony Letai, Jennifer R Brown
Pageof 23

Showing results (31-40 of 224) with videos related to

Sort By:
Pageof 23
Hematology/Oncology Clinics of North America|July 17, 2025
The Rapidly Evolving Landscape of the Biology and Therapy of Chronic Lymphocytic LeukemiaJennifer R Brown, Matthew S Davids
Seminars in Hematology|March 27, 2024
Therapeutic targeting of apoptosis in chronic lymphocytic leukemiaInhye E Ahn, Matthew S Davids
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphomaSamuel Y Ng, Matthew S Davids
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2023
Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?Othman Al-Sawaf, Matthew S Davids
Leukemia & Lymphoma|May 6, 2014
Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?Elizabeth A Brem, Matthew S Davids
Blood|March 6, 2020
Breaking through BCL-2 inhibition in CLLStephen J F Chong, Matthew S Davids
Blood|July 18, 2018
The rise of apoptosis: targeting apoptosis in hematologic malignanciesRebecca Valentin, Stephanie Grabow, Matthew S Davids
Blood Cancer Journal|January 8, 2026
First-line treatment for CLL in the era of targeted therapyMatthew S Davids, Stephan Stilgenbauer, Constantine S Tam
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2024
PI3K Inhibitors in Hematology: When One Door Closes…Sigrid S Skånland, Klaus Okkenhaug, Matthew S Davids
Leukemia & Lymphoma|April 26, 2013
Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibitionMatthew S Davids, Anthony Letai, Jennifer R Brown
Pageof 23